US clamps down on sale of 'natural' diabetes drugs from India

Bs_logoImage
Press Trust of India Washington
Last Updated : Jul 25 2013 | 5:00 PM IST
In a major crackdown on illegal sale of India-originating drugs labelled as 'natural' cure for diabetes, the US health regulator FDA has initiated action against 15 companies, including a Gujarat-based drugmaker, for supply of such products.
In separate 'warning letters' issued to Surat-based Amrutam Life Care and 14 other companies, the Food and Drug Administration (FDA) said they have been found to be selling illegal drugs labelled as medicines, dietary supplements and ayurvedic products for diabetes treatment.
Most of these companies have been selling 'India-originating' treatments for diabetes, while at least two of them have suppliers or associate companies in India, as per the letters.
In a separate statement, the FDA said these illegally sold products include "dietary supplements and ayurvedic products -- medicine of the healing arts that originated in India -- with claims to treat, cure, and/or prevent diabetes".
FDA, which has been taking action against many Indian pharmaceutical companies for either deficiencies in their products or at manufacturing facilities, told Amrutam that there might be other violations as well in its products.
India is the second largest drug exporter to the US and Indian drugmakers have a significant presence there. Those having faced FDA action in recent times include Wockhardt, Fresenius Kabi, Ranbaxy, Sun Pharma, Cadilla, Aurobindo Pharma, RPG Life Science, Dabur and Glenmark.
Amrutam has also been told by the US regulator to review all the information put out on its website, blogs, Facebook, Google+ posts and other promotional materials to ensure that the claims do not violate American rules.
Amrutam was selling products like 'Zoom-Zooma-Zoom', Arexi, Diexi and Obexi in the US in the online mode, but the FDA's laboratory tests found them to be "unapproved" drugs with undeclared ingredients.

You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 25 2013 | 5:00 PM IST